Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Lymphoma. Found 29 abstracts

no pagination
Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn MJ, Chavez JC, Calzada O, Lansigan F, Nasheed H, Barta SK, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri F, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, Evens AM, Cohen JB, Flowers CR, Fenske TS, Hamadani M. Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. American journal of hematology. 2017 Feb;92(2):161-70.
Zaorsky NG, Williams GR, Barta SK, Esnaola NF, Kropf PL, Hayes SB, Meyer JE. Splenic irradiation for splenomegaly: A systematic review. Cancer Treat Rev. 2017 Feb;53:47-52.
Kelly KR, Gabrail N, Weitman S, Sarantopoulos J, Olszanski AJ, Edenfield W, Venitz J, Reddy G, Yang A, Hasal SJ, Lockhart AC. Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment. Cancer Chemother Pharmacol. 2016 Nov;78(5):929-39.
Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res. 2016 Jan;22(1):34-43.
Zaorsky NG, Williams GR, Barta SK, Esnaola NF, Kropf PL, Hayes SB, Meyer JE. Splenic irradiation for splenomegaly: A systematic review. Cancer Treat Rev. 2016 Dec 22;53:47-52.
Zaorsky NG, Williams GR, Barta SK, Esnaola NF, Kropf PL, Hayes SB, Meyer JE. Splenic irradiation for splenomegaly: A systematic review. Cancer Treat Rev. 2016 Dec 22;53:47-52.
Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller S, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cavalli F, Lister TA, Cheson BD. Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al [Letter]. J Clin Oncol. 2015 Apr;33(10):1221-3.
Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller S, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cavalli F, Lister TA, Cheson BD. Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al. J Clin Oncol. 2015 Apr;33(10):1221-3.
Barta SK, Samuel MS, Xue X, Wang D, Lee JY, Mounier N, Ribera JM, Spina M, Tirelli U, Weiss R, Galicier L, Boue F, Little RF, Dunleavy K, Wilson WH, Wyen C, Remick SC, Kaplan LD, Ratner L, Noy A, Sparano JA. Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. Annals of Oncology. 2015 Jan;26(5):958-66.   PMCID: 4405278
Urbano-Ispizua A, Pavletic SZ, Flowers ME, Klein JP, Zhang MJ, Carreras J, Montoto S, Perales MA, Aljurf MD, Akpek G, Bredeson CN, Costa LJ, Dandoy C, Freytes CO, Fung HC, Gale RP, Gibson J, Hamadani M, Hayashi RJ, Inamoto Y, Inwards DJ, Lazarus HM, Maloney DG, Martino R, Munker R, Nishihori T, Olsson RF, Rizzieri DA, Reshef R, Saad A, Savani BN, Schouten HC, Smith SM, Socie G, Wirk B, Yu LC, Saber W. The Impact of Graft Versus Host Disease on Relapse Rate in Patients with Lymphoma Depends on the Histological Sub-Type and the Intensity of the Conditioning Regimen. Biol Blood Marrow Transplant. 2015 May 14;21(10):1746-53.   PMCID: 4568162
Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cheson BD. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Journal of Clinical Oncology. 2014 Sep;32(27):3048-58.   PMCID: 5015423
Suresh T, Lee LX, Joshi J, Barta SK. New antibody approaches to lymphoma therapy. J Hematol Oncol. 2014 Sep;7:58.   PMCID: 4172963
Gitelson E, Al-Saleem T, Robu V, Millenson MM, Smith MR. Pediatric nodal marginal zone lymphoma may develop in the adult population. Leukemia & Lymphoma. 2010 Jan;51(1):89-94.   PMCID: not NIH funded
Xu J, Testa JR. DLX5 (distal-less homeobox 5) promotes tumor cell proliferation by transcriptionally regulating MYC. The Journal of biological chemistry. 2009 Jul 31;284(31):20593-601.   PMCID: PMC2742824
Hoppe RT, Advani RH, Ambinder RF, Bierman PJ, Bloomfield CD, Blum K, Dabaja B, Djulbegovic B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hudson MM, Kaminski MS, Love G, Maloney DG, Mansur D, Mauch PM, Moore JO, Schilder RJ, Weiss LM, Winter JN, Yahalom J, Zelenetz AD, National Comprehensive Cancer N. Hodgkin disease/lymphoma. J Natl Compr Canc Netw. 2008 Jul;6(6):594-622.
Narra K, Borghaei H, Al-Saleem T, Hoglund M, Smith MR. Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: report of two cases and review of the literature. Leukemia Research. 2006 Jan;30(1):109-14.
Cordera F, Scott W. Lymphatic drainage patterns of thoracic malignancies. Journal of Bronchology. 2005 Jan;12(4):254-66.
Rogers B. Looking at lymphoma and leukemia. Nursing. 2005 Jul;35(7):56-63; quiz 63-4.
Al-Saleem TI. Re: Lin and Gray - immunoproliferative small intestinal disease. Am J Gastroenterol. 2003 Feb;98(2):501.
Giantonio BJ, Hochster H, Blum R, Wiernik PH, Hudes GR, Kirkwood J, Trump D, Oken MM. Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group. Invest New Drugs. 2001 Jan;19(1):89-92.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Lymphoma

Lymphoma therapy Cancer Antineoplastic Agents Treatment Outcome Radiotherapy Leukemia Meta-analysis X-Ray Computed Tomography radionuclide imaging Female Fluorodeoxyglucose F18 Positron-Emission Tomography Myelofibrosis Splenomegaly Toxicity Palliation Middle Aged therapeutic use Radiopharmaceuticals Radiation oncology Aged pathology methods Monoclonal Antibodies Neoplasm Drug Resistance dt [Drug Therapy] adverse effects drug therapy Neoplasm Staging Local Neoplasm Recurrence Drug Administration Schedule Male diagnosis Human metabolism Adult follicular lymphoma Pyrimidines hodgkins-disease Pure Red-Cell Aplasia Proto-Oncogene Proteins c-akt Lymphatic drainage derivatives Monoclonal) 0 (Antibodies Up-Regulation Genes Lung Neoplasms Spleen classification Maximum Tolerated Dose Esophagus Middle Age Homeodomain Proteins Interferon Inducers 80 and over Aged adult Polylysine Lymphocyte Specific Protein Tyrosine Kinase p56(lck) diagnostic use Non-US Gov't Research Support Lymphocytic Leukemia-Chronic Non-Hodgkin International Cooperation Dose Fractionation Graft-versus-host disease Diffuse large B-cell lymphoma Burkitt lymphoma Hematopoietic Stem Cell Transplantation Hematologic Neoplasms b-cell lymphoma Patient Selection Thrombocytopenia genetics myc Social Support nu [Nursing] 0 (rituximab) Neoplastic Gene Expression Regulation Lung US Gov't Support-PHS Kidney Neoplasms ad [Administration & Dosage] Prognosis Survival Patient Education Predictive Value of Tests Rituximab pediatric malignancy Retreatment radiation effects Neutropenia immunology mt [Methods] Hodgkin Disease Antineoplastic Combined Chemotherapy Protocols Mesothelioma Poly I-C radiotherapy Immunoproliferative Small Intestinal Disease Biomarkers di [Diagnosis] 0 (Antineoplastic Combined Chemotherapy Protocols) IPI Proto-Oncogene Proteins c-myc clinical presentation chemically induced enzymology Protein Binding Genetic Transcription AIDS Renal Neoplasm Antigens Genetic Promoter Regions Immunotherapy Molecular Targeted Therapy progressive transformation pharmacology B cell HIV differentiation lymphoid malignancies germinal-centers Mucosa-Associated Lymphoid Tissue Lymphoma variant 0 (Antineoplastic Agents) antagonists & inhibitors administration & dosage Transcription Factors Use] Mice Cell Proliferation Pralatrexate Drug Monitoring Tumor Cell Line rt [Radiotherapy] Time Factors Base Sequence Transgenic Mice Cyclopentanes Multiple Myeloma pa [Pathology] analogs & derivatives Ubiquitins complications Neoplasms Molecular Sequence Data marginal zone lymphoma Pharmacokinetics co [Complications]
Last updated on Wednesday, September 06, 2017